Leila Dardaei Alghalandis

Title: Leila Dardaei Alghalandis: Innovator in Pharmaceutical Combinations

Introduction

Leila Dardaei Alghalandis is a notable inventor based in Malden, MA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug combinations. Her work focuses on addressing proliferative diseases through targeted therapies.

Latest Patents

Leila Dardaei Alghalandis holds a patent for a pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor. This patent describes a combination that includes an ALK inhibitor, either in free form or as a pharmaceutically acceptable salt, along with a SHP2 inhibitor, also in free form or as a pharmaceutically acceptable salt. The patent outlines the uses of this combination in treating proliferative diseases and methods for administering a therapeutically effective amount of the combination to affected subjects. She has 1 patent to her name.

Career Highlights

Throughout her career, Leila has worked with prominent organizations in the pharmaceutical industry. Notably, she has been associated with Novartis AG and The General Hospital Corporation. Her experience in these institutions has allowed her to contribute to groundbreaking research and development in the field.

Collaborations

Leila has collaborated with esteemed colleagues, including Jeffrey Engelman and Huaixiang Hao. These partnerships have further enhanced her research and innovation efforts in the pharmaceutical sector.

Conclusion

Leila Dardaei Alghalandis is a pioneering inventor whose work in pharmaceutical combinations has the potential to significantly impact the treatment of proliferative diseases. Her contributions to the field exemplify the importance of innovation in healthcare.